The Wall Street Journal Vs. Zoetis
Debunking claims of safety concerns around Zoetis Inc.'s OA pain drug, Librela. Click here for our updated look at ZTS stock ...
2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone
Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.